Last reviewed · How we verify
NCT03955627: REJOIN
REJOIN Trial for Older Breast Cancer Survivors
NA trial testing Relieving Joint Pain and Improving AI Adherence in Older Breast Cancer Survivors (REJOIN) in Breast Cancer Female in 12 participants. Completed in 29 July 2025.
29 July 2025
Quick facts
| Lead sponsor | Wake Forest University Health Sciences |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | supportive care |
| Enrollment | 12 |
| Start date | 15 June 2021 |
| Primary completion | 29 July 2025 |
| Estimated completion | 29 July 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Relieving Joint Pain and Improving AI Adherence in Older Breast Cancer Survivors (REJOIN)
Conditions studied
- Breast Cancer Female — all drugs for Breast Cancer Female →
Sponsor
Wake Forest University Health Sciences
Who can join
60 and older, female only, with Breast Cancer Female. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this pilot intervention study is to test the effectiveness of a self-management approach (combining education- and exercise-based strategies) for improving arthralgia (joint pain) associated with Aromatase Inhibitors (AI) in older breast cancer survivors. Survivors will be recruited from local cancer clinics prior to the completion of primary cancer treatment, as arthralgia can occur soon after initiating AI medication. Participants will be randomized to one of two groups: an enhanced standard care group (AI prescription plus information) or a treatment group (educational classes plus group exercise sessions). Older survivors (≥60 years) will be targeted because they are at increased risk of medication complications which may impede adherence. For the baseline assessment, a cancer-specific geriatric assessment will be conducted and a blood sample will be collected to interpret the effects of the self-management study in the context of geriatric experiences. Additionally, there will be an assessment of knowledge, PA habits, and AI-related joint pain and AI adherence. These will be measured again at 4, 6 and at follow up at 12 months.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
The effect of exercise-based interventions on health-related quality of life and physical function in older patients with cancer receiving medical antineoplastic treatments: a systematic review.
Mikkelsen MK, Juhl CB, Lund CM, Jarden M, et al · · 2020 · cited 31× · PMID 33088348 · DOI 10.1186/s11556-020-00250-w -
Study design and methods for the using exercise to relieve joint pain and improve AI adherence in older breast cancer survivors (REJOIN) trial.
Bluethmann SM, Truica C, Klepin HD, Olsen N, et al · · 2021 · cited 4× · PMID 34049837 · DOI 10.1016/j.jgo.2021.05.011 -
Adapting an Evidence-Based Exercise and Education Program for Older Breast Cancer Survivors for the REJOIN Trial.
Bluethmann SM, Flores E, Grotte M, Heitzenrater J, et al · · 2023 · cited 2× · PMID 35700977 · DOI 10.1123/japa.2022-0013 -
New genomic and proteomic biomarker discovery in cancer: revolutionizing diagnosis and prognostication.
Rajput M, Pandey M, Dixit R. · · 2026 · PMID 41593642 · DOI 10.1186/s12957-025-04185-3
Verify or expand the search:
- PubMed search for NCT03955627
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer Female
Currently open trials in the same condition.
- NCT07505797 — ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE) · recruiting
- NCT07198724 — ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrin · Phase 1, PHASE2 · recruiting
- NCT07331506 — Validation of the Oncoliq Test for the Early Detection of Breast Cancer. · recruiting
- NCT07214883 — UCF MammoChat: Image Repository · recruiting
- NCT07120100 — Transcranial Magnetic Stimulation for Chemotherapy-Induced Peripheral Neuropathy in Breast and Gynecologic Cancer Surviv · NA · recruiting
Other Wake Forest University Health Sciences trials
Trials by the same sponsor.
- NCT07474090 — Personalized Exercise Program for Survivors of Breast Cancer, STEPS-BC Trial · NA · not yet recruiting
- NCT07282444 — A New Way to Share Radiation Therapy Plans Between Doctors, CORRECT Trial · NA · not yet recruiting
- NCT06876896 — Intra-abdominal Pressure (IAP) During PFA Treatment of A-fib/ A-Flutter · NA · recruiting
- NCT07227051 — Optimizing Self-Monitoring Feedback Delivery for the Treatment of Overweight and Obesity · NA · recruiting
- NCT07215624 — Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03955627 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Wake Forest University Health Sciences
- Last refreshed: 22 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03955627.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing